Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $5.2 million.

  • Ani Pharmaceuticals' Gains from Investment Securities changed N/A to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 573.43%. This contributed to the annual value of $5.3 million for FY2024, which is 1340.4% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $5.2 million for Q3 2025.
  • In the past 5 years, Ani Pharmaceuticals' Gains from Investment Securities ranged from a high of $5.3 million in Q1 2024 and a low of -$1.1 million during Q2 2022
  • In the last 5 years, Ani Pharmaceuticals' Gains from Investment Securities had a median value of $777000.0 in 2021 and averaged $2.1 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Gains from Investment Securities crashed by 24092.66% in 2022, and later soared by 51086.76% in 2023.
  • Ani Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $774000.0 in 2021, then soared by 219.9% to $2.5 million in 2022, then tumbled by 91.28% to $216000.0 in 2023, then skyrocketed by 2375.46% to $5.3 million in 2024, then fell by 1.93% to $5.2 million in 2025.
  • Its Gains from Investment Securities was $5.2 million in Q3 2025, compared to $5.3 million in Q1 2024 and $216000.0 in Q4 2023.